Newsroom   |   Resource Center   |   Careers   |   Contact
Over 200,000 Parkinson's disease patients in the US suffer from levodopa induced dyskinesia.
  Development Approach >
Parkinson's Disease
Read about ADS-5102
Dementia
Read about ADS-8704
Influenza
Read about TCAD
News
Adamas Pharmaceuticals Initiates A Phase 2/3 Clinical Study of ADS-5102 for Parkinson's Disease
Adamas Pharmaceuticals' Triple Combination Antiviral Drug (TCAD) Therapy Is Well Tolerated In Phase 2a Study Of Immunocompromised Patients With Influenza A
 
 
About Adamas | Research & Development | Products | Clinical Trials | Partners
© 2012 Adamas Pharmaceuticals, Inc. Privacy Statement | Terms of Use | Site Users Guide